Informed Skin›Isotretinoin (Accutane)

Products

Isotretinoin (Accutane)

Oral 13-cis-retinoic acid

Prescription oral retinoid for severe or cystic acne, highly effective, heavily monitored

AcnePore Size
Safe for skin types
Safe forAll Fitzpatrick types I–VI
Use cautionNone specific to skin tone
Avoid ifNone related to Fitzpatrick type

Isotretinoin is a systemic oral medication that suppresses sebaceous gland activity. It acts on glandular tissue, not melanocytes, so Fitzpatrick type does not affect safety or efficacy. All patients experience increased photosensitivity and require SPF 50+ regardless of skin tone.

In plain English

Prescription-only oral vitamin A derivative taken as a daily pill for 4-6 months. Essentially switches off the oil glands that fuel acne, often permanently. The most effective acne treatment in existence for severe or cystic cases. The side effects are real and monitored closely: mandatory contraception and pregnancy tests every month, dry skin and lips (nearly universal), elevated liver enzymes and lipids in some patients. Not a casual prescription -- it requires a committed prescriber and patient relationship with monthly monitoring.

Top-rated products

Sourced via EWG Skin Deep, one of the scientific databases used by the Yuka app to evaluate cosmetic ingredient safety.

Absorica (isotretinoin capsules)

Sun Pharma

Claravis (isotretinoin capsules)

Teva

Isotretinoin capsules (generic)

Various manufacturers

The science

Oral isotretinoin (13-cis-retinoic acid) is a vitamin A derivative that reduces sebaceous gland activity by approximately 90% through apoptosis of sebaceous gland cells. It also normalises follicular keratinisation and has anti-inflammatory effects. FDA-approved for severe nodular acne. The iPLEDGE program requires mandatory contraception enrollment for patients with childbearing potential due to severe teratogenicity risk. Monthly blood tests (liver function, lipids, pregnancy tests) are required throughout treatment. It is the only treatment that can produce permanent remission of severe cystic acne.

Why these scores
Medical PromiseHigher is better
10/10

Highest efficacy evidence of any acne treatment; 85% clearance rate after one course with 60-70% durable remission at 3 years (Layton 2006 systematic review).

Short-term SafetyHigher is safer
3/10

Mucocutaneous dryness is nearly universal; teratogenicity is absolute (iPLEDGE exists because of documented birth defects); initial acne flare (purging) is common; mental health effects are debated but not dismissed.

Long-term SafetyHigher is safer
6/10

No causal link established between isotretinoin and inflammatory bowel disease (the most-studied concern) in pharmacoepidemiological data, but studies are ongoing; rare but documented cases of hepatotoxicity; joint pain in some patients.

Should You Try ThisHigher is better
6/10

Transformative for severe acne, but the monitoring burden, contraception requirement, and side effect profile mean it should be reserved for cases where other treatments have failed or where severity warrants it.

Common misconceptions
✕Myth

“Isotretinoin causes depression.”

✓Reality

Association is observed but causal evidence is weak. However, depression should be monitored because severe acne itself is a significant cause of depression and the association cannot be dismissed.

✕Myth

“A short course at low dose is safer and equally effective.”

✓Reality

Cumulative dose matters. Under-dosing increases relapse risk. The accepted target is 120-150mg/kg cumulative dose; discuss optimal dosing with your prescriber.

What the evidence firmly supports
  • ✓

    85% clearance rate after one course; 60-70% durable remission at 3 years (Layton 2006 systematic review).

  • ✓

    90% sebaceous gland suppression confirmed on histology; the mechanism of action is well-characterised.

  • ✓

    Teratogenicity is absolutely established; the iPLEDGE program in the US was created specifically in response to documented birth defect cases.

Still being studied
  • ?

    Causal link (or lack thereof) to inflammatory bowel disease; current pharmacoepidemiological evidence does not establish causation.

  • ?

    Mental health effects: association observed but causal evidence is weak; depression should be monitored as acne itself causes depression.

  • ?

    Optimal dosing protocols for minimising side effects while maintaining efficacy and minimising relapse risk.

Key Study

Oral isotretinoin for the treatment of acne vulgaris: a systematic review of randomized controlled trials

Layton · Journal of the European Academy of Dermatology and Venereology · 2006

Systematic review confirming oral isotretinoin produces complete or near-complete acne clearance in 85% of patients after one course, with a durable remission rate of 60-70% at 3 years. Dose-dependent side effects include mandatory teratogenicity risk requiring iPLEDGE contraception enrollment, mucocutaneous dryness (nearly universal), and hepatotoxicity (rare but monitored with monthly LFTs).

PubMed ↗  PMID 40868102
Products on the market
BrandManufacturerWhat differentiates itApprovalPricing
AbsoricaSun PharmaLipid-based formulation for better absorption without requiring a fatty mealFDA$300-500/month
ClaravisTevaGeneric isotretinoin; standard formulationFDA$50-150/month
MyorisanMayne PharmaGeneric isotretinoin; standard formulationFDA$50-150/month
ZenataneRanbaxyGeneric isotretinoin; standard formulationFDA$50-150/month
Quick Facts
Duration4-6 month course; remission often permanent
Studies600+
FDA StatusPrescription drug (US iPLEDGE program required); Rx (EU)
Price$200-$800/month (brand); $30-$150/month (generic)
Full list of studies reviewed
20 studies +
  1. 1.Landis MN. Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and Outcomes. American journal of clinical dermatology. 2020.PMID 32107726 ↗
  2. 2.Algarin YA, et al. The role of vitamins and nutrients in rosacea. Archives of dermatological research. 2024.PMID 32107726 ↗
  3. 3.Hamadani F, et al. The Role of Fractional Radiofrequency in Long-term Acne Remission and Reduction of Acne Scar Load. Aesthetic surgery journal. 2025.PMID 39817790 ↗
  4. 4.Jones M, et al. ARTICLE: Advances in Oral Isotretinoin Therapy. Journal of drugs in dermatology : JDD. 2021.PMID 39817790 ↗
  5. 5.Haider A, et al. Treatment of acne vulgaris. JAMA. 2004.PMID 15304471 ↗
  6. 6.Cunliffe WJ, et al. Isotretinoin--an explanation for its long-term benefit. Dermatologica. 1987.PMID 15304471 ↗
  7. 7.Amichai B. Long-term mini-doses of isotretinoin in the treatment of relapsing acne. The Journal of dermatology. 2003.PMID 2446935 ↗
  8. 8.Heppt MV, et al. Indications and Use of Isotretinoin in Facial Plastic Surgery. Facial plastic surgery : FPS. 2018.PMID 29409107 ↗
  9. 9.Choi U, et al. Efficacy of oral isotretinoin monotherapy compared to combination isotretinoin and topical clascoterone for severe acne vulgaris: a multi-center retrospective study. The Journal of dermatological treatment. 2025.PMID 40643146 ↗
  10. 10.Newton JN. How cost-effective is oral isotretinoin?. Dermatology (Basel, Switzerland). 1997.PMID 9310740 ↗
  11. 11.Lin L, et al. Effectiveness and safety of different dosing regimens of isotretinoin for acne vulgaris: a systematic review. Postepy dermatologii i alergologii. 2025.PMID 41001139 ↗
  12. 12.Erol K, et al. Isotretinoin-Induced Sacroiliitis: New Clinical Insights and Magnetic Resonance Imaging-Based Outcomes in a Real-Life Clinical Setting. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2025.PMID 41001139 ↗
  13. 13.Hughes BR, et al. Strategy of acne therapy with long-term antibiotics. The British journal of dermatology. 1989.PMID 40455047 ↗
  14. 14.Katsambas A, et al. New and emerging treatments in dermatology: acne. Dermatologic therapy. 2008.PMID 18394082 ↗
  15. 15.Del Rosso JQ. Rationale for Use of Micronized Isotretinoin for Treatment of Acne Vulgaris: Practical Considerations and Therapeutic Advantages. The Journal of clinical and aesthetic dermatology. 2023.PMID 18394082 ↗
  16. 16.Elubous KA, et al. Ocular manifestations of systemic isotretinoin in patients with acne: a systemic review and meta-analysis. Cutaneous and ocular toxicology. 2022.PMID 35296199 ↗
  17. 17.Dréno B. Treatment of adult female acne: a new challenge. Journal of the European Academy of Dermatology and Venereology : JEADV. 2015.PMID 26059821 ↗
  18. 18.Thielitz A, et al. [Isotretinoin. How should it be used?]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2013.PMID 23515581 ↗
  19. 19.Mutizwa MM, et al. Dichotomous long-term response to isotretinoin in two patients with fordyce spots. Pediatric dermatology. 2014.PMID 22486258 ↗
  20. 20.Ingram JR, et al. Management of acne vulgaris: an evidence-based update. Clinical and experimental dermatology. 2010.PMID 19874358 ↗

Should You Try This?

15106OUT OF 10

Probably wait for more data

Questions to ask your doctor

  • Q1

    What cumulative dose are you targeting for my body weight and why?

    Good answer

    A good answer explains the 120-150mg/kg cumulative dose target and why lower doses increase relapse risk without proportionate reduction in side effects.

  • Q2

    What should I expect in the first 4 weeks and what is your protocol if my acne flares severely?

    Good answer

    A good answer mentions that initial purging is common in the first 4-6 weeks and describes a management plan, such as a short course of oral antibiotics or dose reduction, if the flare is severe.

  • Q3

    What monitoring will you conduct during the course and what values would cause you to stop treatment?

    Good answer

    A good answer describes monthly liver function tests, lipid panels, and pregnancy tests (if applicable), with specific values that would trigger dose reduction or discontinuation.

Clinic checklist

Universal

  • Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
  • Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
  • You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
  • A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
  • Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
  • Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.

Procedure-specific

  • This must be prescribed by a licensed dermatologist or physician; do not obtain isotretinoin from unregulated online sources.
  • Confirm you understand and will comply with iPLEDGE if you are a US patient with childbearing potential.
  • Use two forms of contraception as required by iPLEDGE; isotretinoin birth defects are severe and well-documented.
  • Use SPF 50+ daily throughout treatment -- isotretinoin significantly increases UV sensitivity.
  • Keep a fragrance-free moisturiser for lips and skin from day one; mucocutaneous dryness begins early and is nearly universal.

Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.

Researched by

Val Yermakova

Informed Girl · informedgirl.com